UNIKE Bio Completes Tens of Millions RMB Angel Round Financing

UNIKE (Hangzhou) Biopharmaceutical Technology Co., Ltd. was established in Binjiang District, Hangzhou in April 2026 — an innovative pharmaceutical company driven by frontier original technology. The company focuses on R&D and industrialization of long-acting protein and peptide innovative drugs, committed to building a world-leading source innovation platform for long-acting protein and peptide drugs. Recently, UNIKE completed a tens-of-millions RMB angel financing round, led by Lanhe Capital.

The company brings together world-class R&D talent, with a core team from top global research institutions and leading pharmaceutical companies, combining cutting-edge research capabilities with mature new drug industrialization experience. The core technology relies on the ZT long-acting protein and peptide original technology platform, which has undergone more than two decades of continuous iteration and multiple rounds of pilot scale-up validation, featuring a complete technology system, mature processes and scalable production capacity.

Protein and peptide drugs are a core development track for global innovative medicines thanks to their precise targeting, high safety and low side effects. However, common pain points such as short half-life, poor stability, difficult modification and low druggability prevent nearly ten thousand high-quality peptide candidate molecules worldwide from clinical translation. Addressing this global industry bottleneck, the original ZT technology platform of UNIKE, centered on the proprietary ZT carrier, offers outstanding advantages in versatility, standardization, short R&D cycles and low development costs.

The ZT platform benchmarks against the most cutting-edge international drug design concepts, achieving breakthrough innovations in key dimensions such as extending drug half-life, preserving biological activity and designing multi-target molecules — comprehensively improving physicochemical properties and stability, optimizing production processes, and greatly enhancing druggability.

Positioned as a high-barrier, high-efficiency, asset-light and replicable platform-based innovative pharmaceutical company, UNIKE has built a multi-dimensional, sustainable commercialization system covering proprietary pipeline commercialization, domestic and overseas pipeline licensing, customized technology development and global patent licensing services.

Based on the ZT technology platform, the company has strategically laid out more than 20 first-in-class innovative drugs, fully covering high-barrier, high-clinical-value areas such as metabolic diseases, oncology, autoimmune diseases and rare diseases. UNIKE has reached cooperation intentions with multiple multinational pharmaceutical companies and leading domestic pharmaceutical enterprises, steadily advancing pipeline licensing, customized technology development and joint R&D.